| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 21,457 | 303,596 | 303,651 | 106,494 |
| Cost of revenue | 23,112 | 55,912 | 34,757 | 35,991 |
| Gross profit | -1,655 | 247,684 | 268,894 | 70,503 |
| Selling, general, and administrative | 2,039,328 | 1,504,758 | 2,341,347 | 1,523,591 |
| Research and development | 50,818 | 24,293* | -3,211 | -111,670 |
| Impairment of entadfi assets | NaN | 0* | 0 | 0 |
| Impairment of intangibles | NaN | 0* | NaN | NaN |
| Impairment of goodwill | 8,134,000 | 0 | 0 | 594,000 |
| Total operating expenses | 10,224,146 | 1,529,051 | 2,338,136 | 2,005,921 |
| Loss from operations | -10,225,801 | -1,281,367 | -2,069,242 | -1,935,418 |
| Gain on extinguishment of note payable | NaN | 2,158,910.75* | -5,384,719 | NaN |
| Gain on issuance of preferred stock and warrants | NaN | -3,955,658* | 2,543,329 | NaN |
| Interest expense related party | NaN | 0* | 0 | 0 |
| Gain on extinguishment of preferred stock | NaN | -392,488* | 196,244 | NaN |
| Interest expense | 2,244 | 4,247 | 300,069 | 223,097 |
| Change in fair value of warrant liabilities | NaN | NaN | -1,934,000 | 229 |
| Gain on forgiveness of accounts payable | NaN | 0 | 0 | 0 |
| Interest income | NaN | 0.5* | NaN | NaN |
| Change in fair value of subscription agreement liability | NaN | 0 | 0 | -191,038 |
| Change in fair value of contingent warrant liabilities | -1,612 | -16,607* | 36 | NaN |
| Change in fair value of series d warrant liability | NaN | 2,594,409.5* | NaN | NaN |
| Change in fair value of series d derivative liability | -3,955,778 | 3,161,333* | 216,000 | NaN |
| Change in fair value of series e warrant liability | NaN | -1,121,711.75* | NaN | NaN |
| Change in fair value of series e derivative liability | -2,072,590 | 384,753.5* | NaN | NaN |
| Other income (loss) | -16,810 | 262,127 | -8,063 | -22,660 |
| Total other income (loss) | 6,010,926 | 6,951,579 | -6,714,460 | -437,024 |
| Gain before income taxes | -4,214,875 | 5,670,212 | -8,783,702 | -2,372,442 |
| Income tax (expense) benefit | NaN | 525 | 0 | 0 |
| Net gain | -4,214,875 | 5,669,687 | -8,783,702 | -2,372,442 |
| Deemed dividend series c preferred stock | NaN | 0 | 0 | 328,504 |
| Net gain applicable to common stockholders | -4,214,875 | 5,669,687 | -8,783,702 | -2,700,946 |
| Basic EPS | -6.71 | 6.046 | -6.25 | -4.76 |
| Diluted EPS | -6.71 | 6.046 | -6.25 | -4.76 |
| Basic Average Shares | 628,528 | 937,690* | 1,405,469 | 567,648 |
| Diluted Average Shares | 628,528 | 937,690* | 1,405,469 | 567,648 |
Onconetix, Inc. (ONCO)
Onconetix, Inc. (ONCO)